Liaoning Cheng Da Co

Liaoning Cheng Da Co R&D per Employee

The R&D Spending per Employee of Liaoning Cheng Da Co (600739.SS) as of Oct 28, 2026 is 86,329.19 CNY. In the previous year, R&D Spending per Employee was 83,068.91 CNY — a change of 3.92% (higher).

R&D per Employee

86,329.19CNY

YoY

3.92%

Last updated:

R&D Spending per Employee of Liaoning Cheng Da Co is 2025 86,329.19 CNY. R&D Spending per Employee of Liaoning Cheng Da Co was 2024 83,068.91 CNY. It decreases by 3.92% higher compared to the previous year.

The Liaoning Cheng Da Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
20,628.39 CNY
Jan 1, 2019
45,002.10 CNY
Jan 1, 2020
65,287.10 CNY
Jan 1, 2021
69,798.23 CNY
Jan 1, 2022
62,085.99 CNY
Jan 1, 2023
64,728.19 CNY
Jan 1, 2024
83,068.91 CNY
Jan 1, 2025
86,329.19 CNY
The Liaoning Cheng Da Co R&D per Employee history
YEARR&D per EmployeeYoY
86,329.19CNY+3.92%
83,068.91CNY+28.33%
64,728.19CNY+4.26%
62,085.99CNY-11.05%
69,798.23CNY+6.91%
65,287.10CNY+45.08%
45,002.10CNY+118.16%
20,628.39CNY+35.99%
15,169.09CNY-16.25%
18,111.96CNY+14.28%
15,848.80CNY-7.39%
17,113.37CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Liaoning Cheng Da Co Stock analysis

What does Liaoning Cheng Da Co do? Liaoning Cheng Da Co., Ltd. generates revenue through four business segments. The Commodity Trading segment sells pharmaceuticals, oil, coal, and steel to retail and wholesale customers. The Biopharmaceutical Manufacturing segment develops and markets human and animal vaccines. The Energy Development segment extracts and sells oil. The Financial Services segment manages long-term investments and funds. The company serves domestic and international markets with these products and services. The firm's pharmaceutical and commodity trading activities target healthcare providers and industrial clients. Vaccine production caters to medical and veterinary markets. Oil sales focus on energy sector buyers. Investment services attract institutional and private investors. All segments operate across China and global markets. Liaoning Cheng Da's revenue streams include pharmaceutical retail and wholesale, commodity trading, vaccine sales, oil production, and financial fund management. The company's diverse portfolio spans healthcare, energy, and finance sectors. Its operations serve both local and international clients through established distribution channels. Liaoning Cheng Da Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Liaoning Cheng Da Co stock

R&D Spending per Employee of Liaoning Cheng Da Co is 86,329.19 CNY in 2025.

R&D Spending per Employee of Liaoning Cheng Da Co changed from 83,068.91 CNY to 86,329.19 CNY, representing a 3.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Liaoning Cheng Da Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Liaoning Cheng Da Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Liaoning Cheng Da Co

All Key Metrics — Liaoning Cheng Da Co